XyloCor Therapeutics' EXACT clinical trial is a Phase 1/2 multicenter, open-label, single-arm, dose escalation trial for coronary artery disease — the most common type of heart disease — with gene therapy at its center. Hear from CEO Albert Gianchetti on the latest on Cell & Gene: The Podcast and subscribe so you never miss an episode!
By Tim Sandle, Ph.D., Bio Products Laboratory Ltd.
While risks can be reduced to a residual level, it is not possible to eliminate a risk entirely. Such risks are foremost about injury to the patient and to the user. Other associated risks may be to the environment or with any data collected. It is incumbent upon the purchaser or distributor to assess a new supplier of medical devices for the relative risk posed by these devices.
While an influx of new companies and technologies is spurring innovation in the industry, these startups are increasingly in competition for talent and capital. Although a fairly new area with respect to the use of AI, the drug design and development process is ripe for the application of machine learning (ML) and deep learning techniques.
Process intensification (PI) is becoming increasingly well-understood, and its utility is continuously evolving to meet specific manufacturer needs, from product development to manufacturing, whether approached stepwise or end-to-end.
Understand the role training devices and patient education play with regard to self-injection therapies. Review the evolution of injection devices and prefilled syringes, the benefits of training devices combined with patient education, and an empirical look at patient training.